A long-acting FGF21 analogue, pegbelfermin, administered once a day at a dose of 10 or 20 mg for 16 weeks to overweight or obese humans with NASH reduced hepatic steatosis without changes in body weight or bone mineral density [79]. This evidence concerns the gene FGF21 and fatty liver disease.